Clinical Trial Update: T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial comparing T-DM1 alone versus T-DM1 with metronomic temozolomide in HER2-positive breast cancer brain metastases after stereotactic radiosurgery; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastasis
• Breast Cancer

Drugs mentioned

• T-DM1 (ado-trastuzumab emtansine) (ado-trastuzumab emtansine)
• Temozolomide (Temozolomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Cancer, Brain Metastasis | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-10-11